Despite having been established as the primary disease-modifying therapy for individuals with sickle cell anemia, hydroxyurea remains underused among children with the disease, according to data published in JAMA Network Open. However, researchers did note “encouraging trends” in both Michigan and New York state Medicaid programs that point toward increased use of hydroxyurea since
TUESDAY, March 28, 2023 (HealthDay News) Few youths with sickle cell anemia (SCA) receive hydroxyurea despite national guidelines recommending its use, according to a study published online March 24 in JAMA Network Open. Sarah L. Reeves, Ph.D., from University of Michigan in Ann Arbor, and colleagues assessed changes in hydroxyurea use among youths with
A substantial proportion of families of privately insured children with sickle cell anemia pay more than $100 for essential stroke screenings, a high-value service.
2022 MAY 05 By a News Reporter-Staff News Editor at Insurance Daily News Current study results on Blood Research have been published. Funders for this research include Agency for Healthcare Research& Quality, US Department of Health and Human Services, Centers for Medicare and Medicaid Services, Agency for Healthcare Research& Quality.